The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3316-3332

  Kahali, Bhaskar ^a   Yu, Jinlong ^a   Marquez, Stefanie B ^a   Thompson, Kenneth W ^a   Liang, Shermi Y ^a   Lu, Li ^b   Reisman, David ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Brahma; Brahma related gene 1; Chromatin remodeling; Rhabdoid; SWI SNF

Indexed keywords

FLAVOPIRIDOL; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 9; MYOCYTE ENHANCER FACTOR 2; PROTEIN SWI; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; NONHISTONE PROTEIN; SMARCA2 PROTEIN, HUMAN; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR;

ARTICLE; BRM GENE; CANCER CELL LINE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE LOSS; GENE SILENCING; GENETIC POLYMORPHISM; LUNG CANCER; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; RHABDOID TUMOR; RNA INTERFERENCE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOID TUMOR; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84902084206     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1945     Document Type: Article

References (53)

1. Zhang F, Tan L, Wainwright LM, Bartolomei MS and Biegel JA. No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors. Genes Chromosomes Cancer. 2002; 34(4):398-405.
2. Reisman D, Glaros S and Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009; 28(14):1653-1668.
3. Roberts CW, Leroux MM, Fleming MD and Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2002; 2(5):415-425.
4. Kuwahara Y, Charboneau A, Knudsen ES and Weissman BE. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer research. 2010; 70(5):1854-1865.
5. Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CW, Thiele CJ, Weissman B and Smith M. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 2002; 62(1):323-328.
6. Ogino S, Ro TY and Redline RW. Malignant rhabdoid tumor: A phenotype? An entity?-A controversy revisited. Adv Anat Pathol. 2000; 7(3):181-190.
7. Hoot AC, Russo P, Judkins AR, Perlman EJ and Biegel JA. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004; 28(11):1485-1491.
8. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, Lawrence MS, Auclair D, Mora J, Golub TR, Biegel JA, Getz G and Roberts CW. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012; 122(8):2983-2988.
9. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL and Crabtree GR. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. Embo J. 1996; 15(19):5370-5382.
10. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR and Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996; 10(17):2117-2130.
11. Laurent BC, Treich I and Carlson M. Role of yeast SNF and SWI proteins in transcriptional activation. Cold Spring Harb Symp Quant Biol. 1993; 58:257-263.
12. Peterson CL and Workman JL. Promoter targeting and chromatin remodeling by the SWI/SNF complex. Curr Opin Genet Dev. 2000; 10(2):187-192.
13. Klochendler-Yeivin A, Muchardt C and Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002; 12(1):73-79.
14. Gordon V, Rogers C and Reisman D. Alteration to the SWI/SNF complex in human cancers. Oncology Reviews. 2010; 4(2).
15. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH and Roberts CW. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010; 18(4):316-328.
16. Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, Kimura S, Ito T, Yahagi N, Ichinose M, Omata M and Iba H. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005; 24(35):5471-5481.
17. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW and Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007; 26(49):7058-7066.
18. Gramling S and Reisman D. Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene. Lett Drug Des Discov. 2011; 8(1):93-99.
19. Gramling SJ, Kahali B, Marquez SB, Thompson KW, Liang S, Lu L, Aponick A and Reisman D. Flavonoids Reactivate BRM: An Important Co-factor for the Anti-Cancer Gene Effects of Flavonoids. Carcinogenesis. Submitted September 2013.
20. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S and Kalpana GV. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res. 2008; 14(2):523-532.
21. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, Chen Z, Xu W, Roberts H, Shepherd FA, Tsao MS and Reisman D. Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene. 2011.
22. Wang JR, Gramling SJ, Goldstein DP, Cheng D, Chen D, Azad AK, Tse A, Hon H, Chen Z, Mirshams M, Simpson C, Huang SH, Marquez S, O'Sullivan B, Liu FF, Roberts H, et al. Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. Carcinogenesis. 2013; 34(5):1012-1017.
23. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK and Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003; 63(3):560-566.
24. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, Hong K, Settnek S, Gupta A, Buetow K, Hewitt S, Travis WD and Jen J. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004; 10(13):4314-4324.
25. Kahali B, Gramling SJ, Marquez SB, Thompson K, Lu L and Reisman D. Identifying targets for the restoration and reactivation of BRM. Oncogene. 2013.
26. Bertos NR, Wang AH and Yang XJ. Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol. 2001; 79(3):243-252.
27. DeCristofaro MF, Betz BL, Wang W and Weissman BE. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene. 1999; 18(52):7559-7565.
28. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A and Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998; 394(6689):203-206.
29. Muchardt C and Yaniv M. When the SWI/SNF complex remodels.the cell cycle. Oncogene. 2001; 20(24):3067-3075.
30. Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W, Jr., Murchardt C, Yaniv M, Sherman LS, Knudsen ES and Weissman BE. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 2002; 21(8):1196-1207.
31. Gramling S, Rogers C, Liu G and Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene. 2011; 30(29):3289-3294.
32. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H and Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochemical pharmacology. 1997; 53(11):1649-1657.
33. Shen KH, Hung SH, Yin LT, Huang CS, Chao CH, Liu CL and Shih YW. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Molecular and cellular biochemistry. 2010; 333(1-2):279-291.
34. Strober BE, Dunaief JL, Guha and Goff SP. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol. 1996; 16(4):1576-1583.
35. Lepley DM and Pelling JC. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinog. 1997; 19(2):74-82.
36. Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A and Sausville E. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 1996; 9(6):1143-1168.
37. Yang L, Zhang HW, Hu R, Yang Y, Qi Q, Lu N, Liu W, Chu YY, You QD and Guo QL. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009; 87(6):933-942.
38. Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, Wong J, Seto E and Yang XJ. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol. 2007; 27(4):1280-1295.
39. Haberland M, Arnold MA, McAnally J, Phan D, Kim Y and Olson EN. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol Cell Biol. 2007; 27(2):518-525.
40. Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE and Knudsen ES. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem. 2002; 277(7):4782-4789.
41. Reincke BS, Rosson GB, Oswald BW and Wright CF. INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells. J Cell Physiol. 2003; 194(3):303-313.
42. Wallberg AE, Neely KE, Hassan AH, Gustafsson JA, Workman JL and Wright AP. Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain. Mol Cell Biol. 2000; 20(6):2004-2013.
43. Wong K, Xiaoping Qiu, Cheng D, Azad AK, Palepu P, Mirshams M, Patel D, Chen Z, Roberts H, Knox J, Won R, Darling G, Waldron J, Goldstein D, Leighl N, Shepherd F, et al. (2012). Two BRM promoter polymorphisms and risk of early stage (Stage I-II) upper aerodigestive tract cancer risk. ASCO.
44. Cuffe S, Lu Cheng, Abul Kalam Azad, Yonathan Brhane, Dangxiao Cheng, Chen Z, Xin Qiu, Boyd K, Emami M, Leighl NB, Sandy Der, Wei Xu, Frances A. Shepherd, Tsao MS, David Reisman and Liu G. (2013). Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. 2013 ASCO Annual Meeting.
45. Gregoire S and Yang XJ. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol Cell Biol. 2005; 25(6):2273-2287.
46. Sohn DH, Lee KY, Lee C, Oh J, Chung H, Jeon SH and Seong RH. SRG3 interacts directly with the major components of the SWI/SNF chromatin remodeling complex and protects them from proteasomal degradation. J Biol Chem. 2007; 282(14):10614-10624.
47. Gao X, Huang M, Liu L, He Y, Yu Q, Zhao H, Zhou C, Zhang J, Zhu Z, Wan J, Jiang X and Gao Y. Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. PLoS One. 2013; 8(1):e55169.
48. Kit Man Wong, Xiaoping Qiu, Dangxiao Cheng, Abul Kalam Azad, Prakruthi R. Palepu, Maryam Mirshams, Devalben Patel, Zhuo Chen, Heidi Roberts, Jennifer J. Knox, Rebecca Wong, Gail Elizabeth Darling, John N Waldron, David P Goldstein, Natasha B. Leighl, Frances A. Shepherd, et al. The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. ASCO Meeting 2012. 2012; J Clin Oncol 30, 2012 (suppl; abstr 10522).
49. An HX, Claas A, Savelyeva L, Seitz S, Schlag P, Scherneck S and Schwab M. Two regions of deletion in 9p23-24 in sporadic breast cancer. Cancer Res. 1999; 59(16):3941-3943.
50. Neville EM, Stewart M, Myskow M, Donnelly RJ and Field JK. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene. 1995; 11(3):581-585.
51. (2014). A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma. ClinicalTrialgov.
52. Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, Jurgens H, Kool M, Gorlich D, Eveslage M, Jung M, Meisterernst M and Fruhwald M. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC cancer. 2013; 13:286.
53. Reisman DN, Sciarrotta J, Bouldin TW, Weissman BE and Funkhouser WK. The expression of the SWI/SNF ATPase subunits BRG1 and BRM in normal human tissues. Appl Immunohistochem Mol Morphol. 2005; 13(1):66-74.